Blinatumomab improves event-free survival in pediatric B-ALL
Blinatumomab (Blincyto; Amgen) compared with consolidation chemotherapy before allogeneic hematopoietic stem cell transplantation (alloHSCT) in pediatric patients with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia (B-ALL) improved event-free survival, according to data from a Phase 3 study published in JAMA.
After a median follow-up of 22.4 months, 69% of patients treated with blinatumomab compared to 43% of patients treated with chemotherapy were alive and event-free. Of the patients who had Minimal Residual Disease (MRD) at baseline, 93% achieved MRD negative remission following treatment with blinatumomab compared to 24% of those treated with chemotherapy.
The 36-month overall survival estimate was 81.1% and 55.8% in the blinatumomab and chemotherapy groups, respectively.
“Acute lymphoblastic leukemia is the most common type of cancer in children. Unfortunately, approximately 15% of children with high-risk B-ALL relapse after frontline chemotherapy,” said David M. Reese, MD, executive vice president of Research and Development at Amgen in a press release. “There remains an urgent need for novel treatment options for these patients, and the study results support BLINCYTO as a new standard of care consolidation therapy for patients with this aggressive disease.”
Read the full press release here.
Stay Connected! Join Our Newsletter
Contact
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809
+908-505-8899
[email protected]